News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,088 Results
Type
Article (14918)
Company Profile (299)
Press Release (266865)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79857)
Career Advice (163)
Deals (13338)
Drug Delivery (39)
Drug Development (50793)
Employer Resources (31)
FDA (5867)
Job Trends (5170)
News (145228)
Policy (10085)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21770)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (244)
Approvals (6062)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (103)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3163)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (578)
Cervical cancer (14)
Clinical research (43810)
Collaboration (1168)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1101)
CRISPR (88)
C-suite (565)
Cystic fibrosis (112)
Data (4360)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1383)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (196)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31688)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51744)
Executive appointments (628)
FDA (7634)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (992)
Gene editing (185)
Generative AI (22)
Gene therapy (497)
GLP-1 (507)
Government (1150)
Grass and pollen (3)
Guidances (166)
Healthcare (6614)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (71)
Infectious disease (1211)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7347)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (425)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (132)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6623)
Metabolic disorders (733)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1965)
Neurotech (1)
NextGen: Class of 2026 (2035)
Non-profit (868)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (165)
Parkinson's disease (232)
Partnered (12)
Patents (306)
Patient recruitment (346)
Peanut (44)
People (26689)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15494)
Phase 2 (20321)
Phase 3 (12887)
Pipeline (3356)
Policy (91)
Postmarket research (878)
Preclinical (6540)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (661)
Real estate (1453)
Recruiting (12)
Regulatory (9934)
Reports (19)
Research institute (974)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (140)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (33)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Last 7 days (315)
Last 30 days (1102)
Last 365 days (17757)
2026 (1965)
2025 (18103)
2024 (20548)
2023 (22420)
2022 (26824)
2021 (27808)
2020 (23361)
2019 (16230)
2018 (11742)
2017 (13763)
2016 (11853)
2015 (14365)
2014 (10406)
2013 (7491)
2012 (7556)
2011 (7632)
2010 (7439)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18276)
Australia (3114)
California (7142)
Canada (1858)
China (784)
Colorado (249)
Connecticut (255)
Delaware (237)
Europe (39268)
Florida (912)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (398)
India (36)
Indiana (162)
Iowa (8)
Japan (228)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5630)
Michigan (110)
Minnesota (252)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1663)
New Mexico (13)
New York (1775)
North Carolina (837)
North Dakota (6)
Northern California (3516)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2831)
Tennessee (40)
Texas (921)
United States (23545)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
282,088 Results for "abata therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
September 16, 2024
·
3 min read
Genetown
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events
Abata Therapeutics, a company focused on translating the biology of regulatory T cells into transformational medicines for patients living with severe autoimmune and inflammatory diseases, announced that company leadership will present and participate in the following investor and industry events.
August 28, 2023
·
2 min read
Genetown
Abata Therapeutics to Present at Upcoming Investor and Industry Events in June
Abata Therapeutics today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June.
May 31, 2023
·
1 min read
Press Releases
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
August 23, 2024
·
3 min read
Business
Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer
Abata Therapeutics today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
April 20, 2023
·
4 min read
Genetown
Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes
Abata Therapeutics today announced its second development candidate, ABA-201, which has the potential to be a disease-modifying Treg cell therapy for patients with type 1 diabetes (T1D) who have remaining beta (β) cell function.
August 24, 2023
·
6 min read
Business
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors
Abata Therapeutics today announced the appointment of David Kaufman, M.D., Ph.D., partner at Third Rock Ventures, to its board of directors.
March 9, 2023
·
3 min read
Press Releases
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
August 15, 2024
·
2 min read
Business
Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer
Abata Therapeutics today announced that it has appointed Ellen Cahir-McFarland, Ph.D., as its Chief Scientific Officer.
December 7, 2022
·
3 min read
FDA
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
July 9, 2024
·
3 min read
1 of 28,209
Next
